AXA Framlington Biotech Z Inc (FUND:BRJZVL2) - Fund price - Overview

Fund Report

AXA Framlington Biotech Fund Z INC

Key Stats
Morningstar® CategorySector Equity Biotechnology
Manager NameLinden Thomson
Inception Date19/01/2015
NAV 20/07/2017GBX 111.90
Day Change2.10%
12 Month Yield0.00%
Dividend FrequencySemi-Annually
Net Assets (mil) 30/06/2017520.91 GBP
Wrapper AvailabilityAll
Our Minimum Initial Investment1.00 Share
Pricing FrequencyDaily
Dealing Cut off Time10:30:00
Regular InvestmentYes
Actual Initial Charge0.00%
Exit Charge-
Custody ChargeYes
Fund Ongoing Charge0.83%
Fund Rebate-

Morningstar Rating™


Morningstar Sustainability Rating

Above Average

Above Average

Sustainability Rating as of 31/05/2017


Fund Benchmark

NASDAQ Biotechnology TR USD

Morningstar® Benchmark

MSCI World/Biotechnology NR USD

Growth Of 10,000 (GBP) 30/06/2017

How has this security performed
  • Fund: AXA Framlington Biotech Fund Z INC
  • Category: Sector Equity Biotechnology
  • Benchmark: MSCI World/Biotechnology NR USD
Trailing Returns % (GBP) 20/07/2017
3 Years Annualised19.2019.8420.68
5 Years Annualised22.8022.0628.30
10 Years Annualised17.2817.8821.60

Morningstar SRRI

Lower Risk
Higher Risk
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Potentially Lower ReturnsPotentially Higher Returns
Source: Morningstar

Investment Objective

The objective is to provide long-term capital appreciation by investing principally in equity securities of companies in biotechnology, genomic and medical research industries worldwide.

Portfolio Profile30/06/2017

AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.